* Affymetrix Inc., of Santa Clara, Calif., received No. 5,795,716, "Computer-Aided Visualization and Analysis System for Sequence Evaluation." The patent relates to a computer program that determines the identity of an unknown base or bases in nucleic acid samples.

* Celgene Corp., of Warren, N.J., received No. 5,798,368 for both composition of matter and therapeutic uses of compounds in the IMiD family of immunological drugs. The IMiDs are a class of immunomodulators that selectively inhibit inflammatory cytokines, especially tumor necrosis factor-alpha, and stimulate anti-inflammatory cytokines.

* Cytel Corp., of San Diego, received No. 5,753,631 for Cylexin, its lead therapeutic compound, for the treatment of inflammatory and related conditions. Cylexin is in Phase II/III trials for the prevention of reperfusion injury in newborn infants undergoing cardiac surgery requiring cardiopulmonary bypass. Cylexin is a selectin inhibitor compound designed to block white cell adhesion.

* EntreMed Inc., of Rockville, Md., received No. 5,792,845, for composition of matter claims for the gene encoding Angiostatin protein.

* GeneMedicine Inc., of The Woodlands, Texas, has rights to No. 5,792,751, "Transfection of Cells Associated with Fluid Spaces," and No. 5,786,340, "Gene Therapy Using the Intestine." The patents were awarded to Baylor College of Medicine, of Houston, and exclusively licensed to GeneMedicine.

* Guilford Pharmaceuticals Inc., of Baltimore, has rights to four patents in its FKBP-neuroimmunophilin ligand neurotrophic program, including broad methods for treating neurological diseases with immunophilin ligands. The patents are No. 5,795,908, "Small Molecule Inhibitors of Rotamase Enzyme Activity"; No. 5,798,355, "Inhibitors of Rotamase Enzyme Activity"; No. 5,801,197, "Rotamase Enzyme Activity Inhibitors"; and No. 5,801,187, "Heterocyclic Esters and Amides."

* Idun Pharmaceuticals Inc., of La Jolla, Calif., received No. 5,786,173, "MCH4 and MCH5, Apoptotic Proteases, Nucleic Acids Encoding and Methods of Use." The apoptotic proteases MCH4 and MCH5 (also known as caspase 10 and caspase 8), were discovered at Thomas Jefferson University, in Philadelphia, and licensed exclusively to Idun. Caspases are cystein proteases that function in the effector phase of apoptosis. Caspases 8 and 10 are coupled to specific cell surface receptors that, when bound by the cytokine ligands, instruct cells to undergo apoptosis.

* Integra LifeSciences Corp., of Plainsboro, N.J., has rights to four patents relating to compounds based on the arginine-glycine-aspartic amino acid sequence that can reduce or inhibit bone resorption, angiogenesis and restenosis. The patents, licensed exclusively to Integra by the Burnham Institute, of LaJolla, Calif., are Nos. 5,770,565, 5,759,996, 5,792,745, and 5,773,412. These relate to the field of bone metabolism and have application in treatment of osteoporosis.

* Onyx Pharmaceuticals Inc., of Richmond, Calif., received No. 5,801,029, covering the use of modified adenoviruses and adenoviral compositions, and other DNA viruses, which lack viral proteins that bind to the tumor suppressor protein Rb to treat cancer patients whose tumors lack Rb function.

* Targeted Genetics Corp., of Seattle, and the University of Pittsburgh received a patent protecting a new class of lipid-based systems that can be used as vehicles for efficient gene delivery. The patent covers cationic lipid formulations (LPD vectors) that are comprised of cationic lipid, polycation (positively charged polymer molecule) and DNA/nucleic acid.

* Unigene Laboratories Inc., of Fairfield, N.J., received a notice of allowance for a patent covering the oral delivery of salmon calcitonin for the treatment of osteoporosis.